Literature DB >> 32021598

A Novel Pathological ARSB Mutation (c.870G>A; p.Trp290stop) in Mucopolysaccharidosis Type VI Patients.

Veysel S Hançer1, Murat Büyükdoğan2, Anila Babameto-Laku3.   

Abstract

Mucopolysaccharidosis (MPS) type VI, also known as Maroteaux-Lamy syndrome, is a lysosomal storage disorder, characterized by the deficiency of the arylsulfatase B enzyme. The clinical phenotype and severity of the illness varies according to the residual enzyme activity. Typical features are a short stature, shortened trunk, protuberant abdomen, flexed-knee stance, arched back, corneal clouding, joint stiffness and contractures as well as a waddling gait. Patients typically have Hurler-like dysmorphic facial features: microcephaly, prominent forehead and eyes, a broad nose, low nasal bridge, thick lips, and hyperplastic gums with widely spaced teeth. Complications of the illness include obstructive airway, cardiac valvular problems, splenomegaly, hernias, and pneumonia. Unlike other MPS diseases, MPS VI is characterized by normal intellectual development. Since the disease is due to deficient glycosaminoglycan (mucopolysaccharide) metabolism, elevated urinary glycosaminoglycan levels are a main indicator of MPS. Diagnosis is confirmed by enzyme assays, specifically low arylsulfatase B activity in conjunction with the normal activity of other lysosomal enzymes. Enzyme replacement therapy and hematopoietic stem cell therapy are showing positive results in the management of the condition. The more severely affected patients, with a rapidly advancing form of the disease, have a short life span and succumb, most commonly to heart failure, by early adulthood. The frequency of ARSB variants in patients with MPS VI are as follows: 59.5% missense, 13.5% small deletions, 12% nonsense, 5% splice site or intronic variants, 3% small duplications, 3% large deletions, and 1% stop-loss. We report an Albanian family with siblings diagnosed with MPS Vl after clinical examination, biochemical tests, and molecular analysis. Hereby, a novel c.870G>A nonsense homozygous mutation was found responsible for the loss of the enzyme activity.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  ARSB; Mucopolysaccharidosis type VI; Mutation; c.870G>A

Year:  2019        PMID: 32021598      PMCID: PMC6997791          DOI: 10.1159/000502597

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  9 in total

1.  Novel Mutations, Including a Large Deletion in the ARSB Gene, Causing Mucopolysaccharidosis Type VI.

Authors:  Chupong Ittiwut; Sukanya Boonbuamas; Chalurmpon Srichomthong; Rungnapa Ittiwut; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Genet Test Mol Biomarkers       Date:  2016-10-31

2.  Head Circumference Charts for Turkish Children Aged Five to Eighteen Years.

Authors:  Bülent Kara; Nilay Etiler; Ayşen Aydoğan Uncuoğlu; Hülya Maraş Genç; Esen Ulak Gümüşlü; Gülbin Gökçay; Andrezej Furman
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

3.  Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations.

Authors:  Piranit Nik Kantaputra; Hulya Kayserili; Yeliz Guven; Warissara Kantaputra; Mehmet C Balci; Pranoot Tanpaiboon; Napaporn Tananuvat; Anusha Uttarilli; Ashwin Dalal
Journal:  Am J Med Genet A       Date:  2014-03-27       Impact factor: 2.802

4.  Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy.

Authors:  Litsa Karageorgos; Doug A Brooks; Paul Harmatz; David Ketteridge; Anthony Pollard; Elizabeth L Melville; Emma Parkinson-Lawrence; Peter R Clements; John J Hopwood
Journal:  Mol Genet Metab       Date:  2006-12-11       Impact factor: 4.797

5.  Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy.

Authors:  L Karageorgos; P Harmatz; J Simon; A Pollard; P R Clements; D A Brooks; John J Hopwood
Journal:  Hum Mutat       Date:  2004-03       Impact factor: 4.878

Review 6.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

7.  Mutational analysis of 105 mucopolysaccharidosis type VI patients.

Authors:  Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood
Journal:  Hum Mutat       Date:  2007-09       Impact factor: 4.878

8.  Enzymatic Screening and Diagnosis of Lysosomal Storage Diseases.

Authors:  Chunli Yu; Qin Sun; Hui Zhou
Journal:  N Am J Med Sci (Boston)       Date:  2013

Review 9.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

  9 in total
  3 in total

1.  Compound heterozygous missense mutations in a Chinese mucopolysaccharidosis type VI patient: a case report.

Authors:  Ming-Fang He; Ji Yang; Meng-Jie Dong; Yin-Ting Wang; Hai Liu
Journal:  BMC Ophthalmol       Date:  2021-05-13       Impact factor: 2.209

Review 2.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

Review 3.  Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.

Authors:  Francesca D'Avanzo; Alessandra Zanetti; Concetta De Filippis; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.